Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles
improve progression-free survival in patients with glioblastoma included in this study,
randomized according to o6-methylguanine-DNA-methyltransferase (MGMT) methylation status and
residual disease or not, to receive an additional 6 cycles of temozolomide.